Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 20/20 | 0.87 |
| ▸ | HTR1B | P28222 | 10/20 | 0.82 |
| ▸ | DRD2 | P14416 | 1/20 | 0.75 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.75 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.75 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.75 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6813001 | 0.93 | HTR1D (1.00) | HTR1DHTR1BDRD2ADRA1DSLC6A4 | |
| SCHEMBL6812410 | 0.90 | HTR1D (1.00) | HTR1DHTR1BDRD2ADRA1DSLC6A4 | |
| SCHEMBL6808570 | 0.86 | HTR1D (0.65) | HTR1DHTR1BDRD2ADRA1DSLC6A4 | |
| SCHEMBL6811135 | 0.86 | HTR1D (1.00) | HTR1DHTR1BDRD2ADRA1DSLC6A4 | |
| SCHEMBL6811345 | 0.86 | HTR1D (1.00) | HTR1DHTR1BDRD2ADRA1DSLC6A4 | |
| SCHEMBL6816613 | 0.84 | HTR1D (1.00) | HTR1DHTR1BDRD2ADRA1DSLC6A4 | |
| SCHEMBL6811841 | 0.83 | HTR1D (0.81) | HTR1DHTR1BDRD2ADRA1DSLC6A4 | |
| SCHEMBL6808247 | 0.81 | HTR1D (1.00) | HTR1DHTR1BDRD2ADRA1DSLC6A4 | |
| SCHEMBL6811773 | 0.80 | HTR1D (1.00) | HTR1DHTR1BDRD2ADRA1DSLC6A4 | |
| SCHEMBL6808316 | 0.79 | HTR1D (0.84) | HTR1DHTR1BDRD2ADRA1DSLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040122001-A1 | Pharmaceutical compounds | ELI LILLY AND COMPANY | 2004-06-24 | — | — | US | disclosed |
| EP-1345930-A2 | PHARMACEUTICAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 2003-09-24 | — | — | EP | disclosed |
| WO-2002050067-A2 | PHARMACEUTICAL HETEROCYCLIC COMPOUNDS | ELI LILLY AND COMPANY (US) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122001-A1 | Pharmaceutical compounds | CYP2D6, LPXN, CYP1B1 | HTR1D 124/4885HTR1B 373/4885DRD2 1606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.